

BIOSPECTRA

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	26-Sep-2018	26-Sep-2021	: Date of Next Review
Prepared By:	Jamie Storm	Not Applicable	: Supersedes
QA/QC Approval:	Amy Yenko	Dora Meissner via proxy Crystal Hamelburg	: Management Approval
Reason for Revision:	See Revision History in ensur		

UREA

CERTIFICATE OF ANALYSIS

BIO ACTIVE GRADE / UR2220 – G500

LOT: UR2220-002-0918

NH₂CONH₂ Δ F.W. 60.06 g/mol. Δ CAS# 57-13-6

Manufacture Date: 04/23/2018

Retest Date: 10/31/2020

Manufacturing Site: 100 Majestic Way, Bangor PA, 18013

Packaging Date: 09/24/2018 Packaging Site: 100 Majestic Way, Bangor PA, 18013

Meets or Exceeds USP Specifications

ANALYSIS	SPECIFICATION	TEST RESULT	
Alcohol Insoluble Matter	0.04% max.	0.0080%	
Appearance and Color	White / Crystals	White / Crystals	
Assay	98.0-102.0%	100.23%	
Enzymes	DNase	None Detected	
	RNase	None Detected	
	Protease	None Detected	
Heavy Metals	10 ppm max.	<10ppm	
Identification A (IR)	Passes Test	Passes Test	
Identification B	Passes Test	Passes Test	
Impurities	Urea RCA	<0.1%	
	Total	<2.0%	
	Unspecified	<0.1%	
Insoluble Matter	0.010% max.	<0.0015%	
Loss on Drying	1.0% max.	0.1478%	
Melting Range	132-135 °C	133.8 – 134.8 °C	
Residue on Ignition	0.010% max.	<0.0075%	
	Arsenic (As)	5 ppm max.	< 5 ppm
	Copper (Cu)	5 ppm max.	< 5 ppm
	Iron (Fe)	5 ppm max.	< 5 ppm
	Lead (Pb)	5 ppm max.	< 5 ppm

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: 16-000495

The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping, and the prevention of unauthorized appropriation, use, disclosure and copying.

CAUTION STATEMENT: For use in development only and not for commercial distribution.

INTENDED USE: Material represented by this Certificate of Analysis is suitable to be used only as the following: ICH Q7 Compliant cGMP Manufactured Active Pharmaceutical Ingredient for use in Drug Product Manufacturing. The material represented by this Certificate of Analysis is not suitable to be used as a Sterile or Injectable Active Pharmaceutical Ingredient, Drug Product or Household Item.

RESIDUAL SOLVENTS: Based on the manufacturing process and the controlled handling and storage of this product, there is no potential for any of the residual solvents listed in the current USP method <467> Tables 1, 2, 3, or 4 to be present at the specified limits; furthermore, if tested this product would comply with USP/NF requirements.

Prepared by: H. Bennett Date: 9/26/18

Reviewed by: Cynthia R Date: 9/26/18